Table 1 Association between HAMP expression and clinicopathologic features of ccRCC
From: High Hepcidin expression predicts poor prognosis in patients with clear cell renal cell carcinoma
Characteristic | Low expression of HAMP | High expression of HAMP | p |
|---|---|---|---|
n | 265 | 265 | Â |
Age, n (%) | Â | Â | 0.339 |
 <  = 60 | 126 (23.8%) | 138 (26%) |  |
 > 60 | 139 (26.2%) | 127 (24%) |  |
Gender, n (%) | Â | Â | 0.003 |
Female | 110 (20.8%) | 76 (14.3%) | Â |
Male | 155 (29.2%) | 189 (35.7%) | Â |
Pathologic stage, n (%) |  |  |  < 0.001 |
Stage I | 165 (31.3%) | 100 (19%) | Â |
Stage II | 24 (4.6%) | 33 (6.3%) | Â |
Stage III | 53 (10.1%) | 70 (13.3%) | Â |
Stage IV | 22 (4.2%) | 60 (11.4%) | Â |
T stage, n (%) |  |  |  < 0.001 |
T1 | 166 (31.3%) | 105 (19.8%) | Â |
T2 | 27 (5.1%) | 42 (7.9%) | Â |
T3 | 70 (13.2%) | 109 (20.6%) | Â |
T4 | 2 (0.4%) | 9 (1.7%) | Â |
N stage, n (%) | Â | Â | 0.009 |
N0 | 118 (46.3%) | 121 (47.5%) | Â |
N1 | 2 (0.8%) | 14 (5.5%) | Â |
M stage, n (%) |  |  |  < 0.001 |
M0 | 224 (45%) | 196 (39.4%) | Â |
M1 | 21 (4.2%) | 57 (11.4%) | Â |
OS event, n (%) |  |  |  < 0.001 |
Alive | 207 (39.1%) | 150 (28.3%) | Â |
Dead | 58 (10.9%) | 115 (21.7%) | Â |
DSS event, n (%) |  |  |  < 0.001 |
Alive | 227 (43.7%) | 184 (35.5%) | Â |
Dead | 33 (6.4%) | 75 (14.5%) | Â |
PFI event, n (%) | Â | Â | 0.002 |
Alive | 202 (38.1%) | 168 (31.7%) | Â |
Dead | 63 (11.9%) | 97 (18.3%) | Â |